Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 1

Status

Not yet recruiting 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Carcinoma, Non-Small-Cell Lung 59Carcinoma, Hepatocellular 43Colorectal Neoplasms 32Stomach Neoplasms 28Esophageal Squamous Cell Carcinoma 27Squamous Cell Carcinoma of Head and Neck 20Esophageal Neoplasms 14Small Cell Lung Carcinoma 13Neoplasm Metastasis 13Lung Neoplasms 13Head and Neck Neoplasms 12Advanced Solid Tumor 12Cholangiocarcinoma 11Triple Negative Breast Neoplasms 10Rectal Neoplasms 10Nasopharyngeal Carcinoma 10Melanoma 10Uterine Cervical Neoplasms 9Recurrence 9Neoplasms 9Colonic Neoplasms 9Pancreatic Neoplasms 7Urinary Bladder Neoplasms 6Solid Tumor 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Sarcoma 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma 5Hodgkin Disease 5

Interventions

Cyclophosphamide 193fludarabine phosphate 121Peripheral Blood Stem Cell Transplantation 106Etoposide 106Mycophenolic Acid 94Filgrastim 91Doxorubicin 85Whole-Body Irradiation 83Tacrolimus 80Melphalan 78Brentuximab Vedotin 77Busulfan 74Radiotherapy 73fludarabine 67Cyclosporine 67Vinblastine 65Rituximab 60Dacarbazine 56Granulocyte Colony-Stimulating Factor 53Gemcitabine 52Antilymphocyte Serum 51Bleomycin 50Nivolumab 47Methotrexate 47Vincristine 46Prednisone 45Cytarabine 43pembrolizumab 36Carmustine 36Bendamustine Hydrochloride 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Hodgkin Disease × tislelizumab × Clear all
NCT05502250 2026-03-06

HOVON164HL

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Hodgkin Disease

NCT05977673 2025-12-08

FIL_Tisle-HL

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting
28 enrolled
Lymphoid

Hodgkin Disease, Lymphoma

NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Dalian Medical University

Phase 4 Not yet recruiting
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT05627115 2023-11-29

RATiFY

University College, London

Phase 2 Not yet recruiting
80 enrolled
Lymphoid

Hodgkin Disease

NCT04843267 2021-04-13

A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT

Sun Yat-sen University

Phase 2 Unknown
30 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡